SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for myelofibrosis patients who failed standard therapy
Disease control CompletedThis study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease no longer responded well to standard JAK-inhibitor treatment. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo aims to tame deadly transplant complication
Disease control CompletedThis phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a Pre-Transplant drug boost survival in myelofibrosis?
Disease control CompletedThis phase 2 trial looked at whether giving a JAK inhibitor (ruxolitinib) before a donor stem cell transplant helps people with myelofibrosis. The study enrolled 61 patients with primary or secondary myelofibrosis. The goal was to see if this approach improves survival and reduce…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC